Christine Baker, Hookipa’s Chief Business Officer, is responsible for the company’s business development, alliance management, and commercial planning. Christine has more than 30 years of experience with biopharma innovation. Prior to joining HOOKIPA, she was Chief Business Officer at EpicentRx, where she led the partnering activities for multiple clinical-stage oncology assets. Before this, as a Vice President at Novartis, she was a leader in Oncology business development and M&A. Notable deals include the $16 billion multi-asset swap between Novartis and Glaxo SmithKline in 2014 and the collaboration with University of Pennsylvania in 2012 which led to the first-in-class chimeric antigen receptor T-cell (CAR-T) therapy.
In creating the Early Commercial Strategy unit, Christine built a team which worked closely with R&D colleagues to optimize product differentiation and future commercial performance. Christine began her career in Schering-Plough, where she made notable contributions in Research Licensing, Strategic Planning and multiple US and Global Commercial roles, including acting Vice President for Sales and Marketing. Christine earned her undergraduate Chemistry degree magna cum laude from Dartmouth College and an MBA from Rutgers University. She is also a non-executive director (NED) on the Board of TuHURA Biopharma, Inc., a start-up biotechnology company.View Company Website >